Abstract:High overexpression of sigma (σ) receptors (σ1 and σ2 subtypes) in a variety of human solid tumors has prompted the development of σ receptor-targeting radioligands, as imaging agents for tumor detection. A majority of these radioligands to date target the σ2 receptor, a potential marker of tumor proliferative status. The identification of approximately equal proportions of both σ receptor subtypes in prostate tumors suggests that a high affinity, dual σ receptor-targeting radioligand could potentially provide enhanced tumor targeting efficacy in prostate cancer. To accomplish this goal, we designed a series of ligands which bind to both σ receptor subtypes with high affinity. Ligand 3a in this series, displaying optimal dual σ receptor subtype affinity (σ1, 6.3 nM; σ2, 10.2 nM) was radiolabeled with fluorine-18 (18F) to give [18F]3a and evaluated as a σ receptor-targeting radioligand in the mouse PC-3 prostate tumor model. Cellular assays with PC-3 cells demonstrated that a major proportion of [18F]3a was localized to cell surface σ receptors, while ∼10% of [18F]3a was internalized within cells after incubation for 3.5 h. Serial PET imaging in mice bearing PC-3 tumors revealed that uptake of [18F]3a was 1.6 ± 0.8, 4.4 ± 0.3, and 3.6 ± 0.6% ID/g (% injection dose per gram) in σ receptor-positive prostate tumors at 15 min, 1.5 h, and 3.5 h postinjection, respectively (n = 3) resulting in clear tumor visualization. Blocking studies conducted with haloperidol (a nonselective inhibitor for both σ receptor subtypes) confirmed that the uptake of [18F]3a was σ receptor-mediated. Histology analysis confirmed similar expression of σ1 and σ2 in PC-3 tumors which was significantly greater than its expression in normal organs/tissues such as liver, kidney, and muscle. Metabolite studies revealed that >50% of radioactivity in PC-3 tumors at 30 min postinjection represented intact [18F]3a. Prominent σ receptor-specific uptake of [18F]3a in prostate tumors and its subsequent clear visualization with PET imaging indicate potential utility for the diagnosis of prostate carcinoma.

Synthesis and Biological Evaluation of 18F Labeled Fluoro-Oligo-ethoxylated 4-Benzylpiperazine Derivatives for Sigma-1 Receptor Imaging

Synthesis and evaluation of a (18) F-labeled 4-phenylpiperidine-4-carbonitrile radioligand for σ1 receptor imaging.

Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising σ1 receptor imaging agent.

F-Labeled benzylpiperazine derivatives as highly selective ligands for imaging σ receptor with positron emission tomography.

Synthesis and evaluation of novel 18F-labeled spirocyclic piperidine derivatives as σ1 receptor ligands for positron emission tomography imaging

1-(4-[18F]fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging Σ1 Receptors in the Brain.

Synthesis and Evaluation of New 1-Oxa-8-azaspiro[4.5]decane Derivatives As Candidate Radioligands for Sigma-1 Receptors

Synthesis and biological evaluation of novel 4-benzylpiperazine ligands for sigma-1 receptor imaging.

F-18-Labeled 1,4-Dioxa-8-Azaspiro[4.5]Decane Derivative: Synthesis And Biological Evaluation Of A Sigma(1) Receptor Radioligand With Low Lipophilicity As Potent Tumor Imaging Agent

18F-Labeled Indole-Based Analogs As Highly Selective Radioligands for Imaging Sigma-2 Receptors in the Brain.

Synthesis and biological evaluation of a radioiodinated spiropiperidine ligand as a potential σ1 receptor imaging agent

Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors

Development of a Highly Specific 18F-Labeled Benzimidazolonebased Sigma-2 Receptor Radioligand for Brain Tumor Imaging

Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

Novel 18F-Labeled Benzimidazolone-Based Radioligands As Highly Selective Sigma-2 Receptor Probes for Tumor Imaging

Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging.

Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP

Positron Emission Tomography Imaging Evaluation of a Novel <SUP>18</SUP>F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Novel Radioligands for Imaging Sigma-1 Receptor in Brain Using Positron Emission Tomography (PET)

[18F]Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System